#BEGIN_DRUGCARD DB01057

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Phospholine Iodide PWS 3mg/5ml (Diluent + Echothiophate Iodide)

# Brand_Names:
Echodide
Phospholine Iodide

# CAS_Registry_Number:
6736-03-4

# ChEBI_ID:
4753

# Chemical_Formula:
C9H23NO3PS

# Chemical_IUPAC_Name:
diethyl {[2-(trimethylazaniumyl)ethyl]sulfanyl}phosphonate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2238076

# Description:
A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.

# Dosage_Forms:
Solution / drops	Ophthalmic

# Drug_Category:
Cholinesterase Inhibitors
Miotics
Parasympathomimetics

# Drug_Interactions:
Succinylcholine	Echothiophate iodide may increase the effect of succinylcholine.

# Drug_Reference:
20673046	Schmidt KG, Horowitz Y, Buckman G, Segev E, Levinger E, Geyer O: Lowering of IOP by echothiophate iodide in pseudophakic eyes with glaucoma. Curr Eye Res. 2010 Aug;35(8):698-702.
7166393	Reddy RH: Echothiophate iodide: its use in accommodative esotropia (high Ac/A ratio). Indian J Ophthalmol. 1982 Jul;30(4):225.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-2.25

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Soluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Echothiophate

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C9H23NO3PS/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5/h6-9H2,1-5H3/q+1

# InChI_Key:
InChIKey=BJOLKYGKSZKIGU-UHFFFAOYSA-N

# Indication:
For use in the treatment of subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02193

# LIMS_Drug_ID:
1057

# Mechanism_Of_Action:
Echothiophate Iodide is a long-acting cholinesterase inhibitor for topical use which enhances the effect of endogenously liberated acetylcholine in iris, ciliary muscle, and other parasympathetically innervated structures of the eye. Echothiophate iodide binds irreversibly to cholinesterase, and is long acting due to the slow rate of hydrolysis by cholinesterase. It causes miosis, increase in facility of outflow of aqueous humor, fall in intraocular pressure, and potentiation of accommodation.

# Melting_Point:
138 Â°C

# Molecular_Weight_Avg:
256.323

# Molecular_Weight_Mono:
256.113625809

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164743139

# Pharmacology:
Echothiophate Iodide is a potent, long-acting cholinesterase inhibitor used as a miotic in the treatment of glaucoma. Echothiophate iodide will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eyedrop therapy.

# Predicted_LogP_Hydrophobicity:
-2.1

# Predicted_LogS:
-3

# Predicted_Water_Solubility:
2.97e-01 g/l

# Primary_Accession_No:
DB01057

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
10547

# PubChem_Substance_ID:
46505944

# RxList_Link:
http://www.rxlist.com/cgi/generic2/phospholine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00942

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCOP(=O)(OCC)SCC[N+](C)(C)C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Echothiophate Iodide
Phospholine
Phospholine Iodide

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects include blurred vision or change in near or distant vision and eye pain.

# Update_Date:
2013-02-08 16:19:52 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Echothiophate

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
2481033	Henderson EG, Post-Munson DJ, Reynolds LS, Epstein PM: Echothiophate and cogeners decrease the voltage dependence of end-plate current decay in frog skeletal muscle. J Pharmacol Exp Ther. 1989 Dec;251(3):810-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
BCHE

# Drug_Target_1_GenBank_ID_Gene:
M32391

# Drug_Target_1_GenBank_ID_Protein:
1311630

# Drug_Target_1_GeneCard_ID:
BCHE

# Drug_Target_1_Gene_Name:
BCHE

# Drug_Target_1_Gene_Sequence:
>1809 bp
ATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC
ATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA
GTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC
TATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG
TCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT
TTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT
TTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG
ATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT
CTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA
TTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG
TTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA
ACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA
AGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG
GTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC
TCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT
CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG
ACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT
AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT
GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA
GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT
TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT
GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG
GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA
TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA
AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGTTGGGCA
AATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC
TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG
AAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG
ACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT
TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG
GGTCTCTAA

# Drug_Target_1_General_Function:
Lipid transport and metabolism

# Drug_Target_1_General_References:
2322535	Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN, Lockridge O: Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry. 1990 Jan 9;29(1):124-31.
2915989	McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, Lockridge O, La Du BN: Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 1989 Feb;86(3):953-7.
3035536	Prody CA, Zevin-Sonkin D, Gnatt A, Goldberg O, Soreq H: Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3555-9.
3067729	Lockridge O: Structure of human serum cholinesterase. Bioessays. 1988 Oct;9(4):125-8.
3115973	Lockridge O, Adkins S, La Du BN: Location of disulfide bonds within the sequence of human serum cholinesterase. J Biol Chem. 1987 Sep 25;262(27):12945-52.
3477799	McTiernan C, Adkins S, Chatonnet A, Vaughan TA, Bartels CF, Kott M, Rosenberry TL, La Du BN, Lockridge O: Brain cDNA clone for human cholinesterase. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6682-6.
3542989	Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL: Complete amino acid sequence of human serum cholinesterase. J Biol Chem. 1987 Jan 15;262(2):549-57.

# Drug_Target_1_HGNC_ID:
HGNC:983

# Drug_Target_1_HPRD_ID:
01519

# Drug_Target_1_ID:
3923

# Drug_Target_1_Locus:
3q26.1-q26.2

# Drug_Target_1_Molecular_Weight:
68419

# Drug_Target_1_Name:
Cholinesterase

# Drug_Target_1_Number_of_Residues:
602

# Drug_Target_1_PDB_ID:
1P0Q

# Drug_Target_1_Pathway:
Heroin Pathway	SMP00407
Irinotecan Pathway	SMP00433

# Drug_Target_1_Pfam_Domain_Function:
PF00135	COesterase
PF08674	AChE_tetra

# Drug_Target_1_Protein_Sequence:
>Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL

# Drug_Target_1_Reaction:
an acylcholine + H2O = choline + a carboxylate

# Drug_Target_1_Signals:
1-28

# Drug_Target_1_Specific_Function:
An acylcholine + H(2)O = choline + a carboxylate

# Drug_Target_1_SwissProt_ID:
P06276

# Drug_Target_1_SwissProt_Name:
CHLE_HUMAN

# Drug_Target_1_Synonyms:
Acylcholine acylhydrolase
Butyrylcholine esterase
Choline esterase II
Cholinesterase precursor
EC 3.1.1.8
Pseudocholinesterase

# Drug_Target_1_Theoretical_pI:
7.47

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01057
